

Contains Nonbinding Recommendations

Draft – Not for Implementation

Investigational IVDs Used in Clinical Investigations of Therapeutic Products

Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Document issued on: December 18, 2017

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document regarding CDRH-regulated devices, contact CDRH's Office of *In Vitro* Diagnostics and Radiological Health at 301-796-5711, or David Litwack at 301-796-6697 or Ernest.Litwack@fda.hhs.gov. For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

Contains Nonbinding Recommendations

Draft – Not for Implementation

Preface

Additional Copies

CDRH

Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 1400025 to identify the guidance you are requesting.

CBER

Additional copies are available from the Center for Biologics Evaluation and Research (CBER), Office of Communication, Outreach, and Development (OCOD), 10903 New Hampshire Ave., Bldg. 71, Room 3128, Silver Spring, MD 20993-0002, or by calling 1-800-835-4709 or 240-402-8010, by email, ocod@fda.hhs.gov or from the Internet at <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>.

Table of Contents

I.	Introduction.....	1
II.	Background.....	2
III.	Policy	3
A.	What is an Investigational IVD?.....	3
B.	IDE Regulation and Investigational IVD Risk in Investigations.....	4
	1) Significant Risk (SR) Devices	5
	2) Non-Significant Risk (NSR) Devices	6
	3) IDE Exempt Investigations	7
C.	Evaluating Whether an Investigational IVD Used in a Clinical Investigation of a Therapeutic Product is Significant Risk	7
	1) Factors to Consider in Making a Risk Determination	8
	2) Investigational IVD Risk and the Design of Clinical Investigations for Therapeutic Products.....	9
	3) How Investigational IVD Risk May Change During the Course of a Clinical Investigation.....	12
D.	Recommendations for IRBs and Sponsors in Evaluating Investigational IVDs in the Context of Clinical Investigations for Therapeutic Products.....	12
	1) Information the Sponsor Should Include in Its Submission to the IRB.....	13
	2) Recommendations for Review Questions for IRBs	14
	3) When Can a Sponsor Begin a Therapeutic Product Trial Involving Use of an Investigational IVD?.....	16
E.	Common Questions about Investigational IVD Use in Clinical Investigations of Therapeutic Products and Compliance with the IDE Regulation	16
F.	Inclusion of Investigational IVD Information in an IND	17
G.	Managing IDEs and INDs for the Same Study.....	18
H.	Q-Submission Meetings.....	19
APPENDIX.	Important Considerations for Sponsors.....	20
A.	Contents of an IDE Application.....	20
B.	FDA Review of IDE Applications.....	23

Investigational IVD Used in Clinical Investigations of Therapeutic Products

Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

Personalized medicine (also referred to as “precision medicine”) relies on the use of *in vitro* diagnostic (IVD) devices¹ to detect and measure biomarkers and other individual characteristics of disease or other conditions with the goal of better directing patient treatment. With the continued growth of personalized medicine, an increasing number of clinical investigations of therapeutic products (also referred to here as therapeutic product trials or studies) are using investigational IVDs to guide the management of subjects in such investigations.² In some cases this has led to the development of an *in vitro* companion diagnostic device that is essential to the safe and effective use of the therapeutic product, once approved.³ The information generated by the use of investigational IVDs in therapeutic product trials may affect important aspects of treatment for the enrolled subjects and, by doing so, directly influence the types of therapeutic products or therapeutic management strategies the subjects may be exposed to during the study. Therefore, use of an investigational IVD in a therapeutic product trial may pose significant risk to subjects. FDA is concerned that sponsors (including sponsor-

¹ See 21 CFR 809.3(a) for the complete definition of *in vitro* diagnostic products.

² For purposes of this guidance, the terms investigation, study, and trial are used interchangeably and have the same meaning.

³ See the guidance entitled “In Vitro Companion Diagnostic Devices” (<http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262327.pdf>) which provides information about FDA’s policies regarding such devices.

Contains Nonbinding Recommendations

Draft – Not for Implementation

31 investigators) and IRBs may not understand that many IVDs used as a critical part of
32 therapeutic product trials are investigational. This guidance document is intended to
33 inform stakeholders, including institutional review boards or institutional review
34 committees (referred to hereafter as IRBs) reviewing clinical investigations, and sponsors
35 that therapeutic product⁴ trials that include investigational IVDs are subject to FDA's
36 Investigational Device Exemption (IDE) regulation (21 CFR Part 812), regardless of the
37 source or manufacturer of the device, in addition to the Investigational New Drug (IND)
38 regulation (21 CFR Part 312).

39
40 In addition, this guidance is intended to aid sponsors and IRBs in making determinations
41 about the nature of risks of investigational IVDs used in therapeutic product studies to
42 streamline the decision-making process, and provides information about: (i) definitions and
43 concepts that are important in assessing investigational IVD risks (see sections III.A - III.C),
44 (ii) the roles and responsibilities of sponsors and IRBs in complying with IDE requirements
45 (sections III.D - III.G), and (iii) FDA's recommendations and requirements for submitting
46 significant risk investigational IVD information in an IDE application (Appendix). The
47 information presented in this document is consistent with FDA regulation of investigational
48 use of IVDs in general.

49
50 FDA's guidance documents, including this draft guidance, do not establish legally
51 enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a
52 topic and should be viewed only as recommendations, unless specific regulatory or statutory
53 requirements are cited. The use of the word *should* in Agency guidance documents means
54 that something is suggested or recommended, but not required.

55 **II. Background**

56 In contrast to other types of devices that act on or in a patient, IVDs are usually used on
57 samples that are removed from or originate in the patient's body.⁵ Despite their use *ex*
58 *vivo*, IVDs may pose risk to patients, e.g., when they provide inaccurate test results that
59 misinform patients' healthcare management decisions. This risk extends to the use of
60 investigational IVDs when their results are used to guide the management of subjects in
61 therapeutic product trials, e.g., to select or classify subjects, assign subjects to therapeutic
62 product arms or doses, or monitor responses to treatment. Such uses have become more
63 common given the increasing number of targeted therapeutic product development
64 programs and potential response biomarkers.

65

⁴ As used in this guidance, *therapeutic product* includes therapeutic, preventive, and prophylactic drugs and biological products. Although this guidance does not expressly address therapeutic devices as therapeutic products intended for use with *in vitro* diagnostics, the principles discussed in this guidance may also be relevant to such devices.

⁵ Note, however, that specimen collection devices are also considered IVD devices.

Contains Nonbinding Recommendations

Draft – Not for Implementation

66 An investigational IVD is an IVD (i.e., a reagent, instrument, or system intended for use in
67 the diagnosis of disease or other conditions⁶) that is the object of an investigation,⁷ and thus
68 is subject to the IDE regulation (21 CFR Part 812). Compliance with the IDE regulation
69 allows the shipment of investigational IVDs and their use in investigations while at the same
70 time providing measures to protect the safety of study subjects. Under the IDE regulation, an
71 approved IDE is required for an investigational device unless it is exempted under 21 CFR
72 812.2(c). Investigational IVDs are often exempt under 21 CFR 812.2(c) from most of the
73 IDE regulation.

74
75 As specified in 21 CFR 812.40, the sponsor is responsible for ensuring IRB review and
76 approval of an investigation.⁸ Sponsor-investigators,⁹ who serve as both sponsors and
77 investigators¹⁰ in an investigation, also assume the responsibility for ensuring IRB review
78 and approval. Sponsors may fail to appropriately recognize and identify to their IRBs the
79 investigational status of IVDs used in therapeutic product trials. FDA is also concerned
80 that sponsors and/or IRBs may not adequately assess and/or describe the risks associated
81 with investigational IVDs. The following sections are intended to provide additional
82 information to sponsors and IRBs to clarify issues relating to the investigational status of
83 IVDs, risk assessment(s) that should be undertaken, and the requirements applicable to
84 investigational IVDs in 21 CFR Parts 50, 56, and 812.

85 **III. Policy¹¹**

86 **A. What is an Investigational IVD?**

87 An investigational IVD is an IVD “that is the object of an investigation” (21 CFR 812.3(g)).
88 An investigation is defined as a “clinical investigation or research involving one or more
89 subjects to determine the safety or effectiveness of a device” (21 CFR 812.3(h)).¹² When an
90 investigational IVD is used to guide the therapeutic management of subjects in a therapeutic

⁶ See 21 CFR 809.3(a) for the complete definition of *in vitro* diagnostic product.

⁷ See 21 CFR 812.3(g) for the complete definition of an investigational device and see 21 CFR 812.3(h) for the definition of investigation.

⁸ *Sponsor* means a person who initiates, but who does not actually conduct, the investigation, that is, the investigational device is administered, dispensed, or used under the immediate direction of another individual. A person other than an individual that uses one or more of its own employees to conduct an investigation that it has initiated is a sponsor, not a sponsor-investigator, and the employees are investigators (21 CFR 812.3(n)).

⁹ *Sponsor-investigator* means an individual who both initiates and actually conducts, alone or with others, an investigation (i.e., an individual under whose immediate direction the investigational device is administered, dispensed, or used). The term does not include any person other than an individual. The obligations of a sponsor-investigator under 21 CFR Part 812 include those of an investigator and those of a sponsor (21 CFR 812.3(o)).

¹⁰ *Investigator* means an individual who actually conducts a clinical investigation, i.e., under whose immediate direction the test article is administered or dispensed to, or used involving, a subject, or, in the event of an investigation conducted by a team of individuals, is the responsible leader of that team (21 CFR 812.3(i)).

¹¹ This guidance is not intended to address investigations of combination products as defined in 21 CFR 3.2(e).

¹² For determining the applicability of the IDE regulation, the relevant definition of investigation is the one found in 21 CFR 812.3(h), not the one found in 21 CFR 56.102(c).

Contains Nonbinding Recommendations

Draft – Not for Implementation

91 product trial, and trial results provide information on the safety and effectiveness of the
92 investigational IVD in addition to the safety and effectiveness of the investigational
93 therapeutic product, FDA believes that the trial falls within the definition in 21 CFR
94 812.3(h). An investigational IVD used in a therapeutic product study might be, for example,
95 a novel IVD, an IVD that is legally marketed¹³ in the U.S. for a different intended use¹⁴, or a
96 legally marketed IVD that has been significantly modified with respect to its technological
97 characteristics. It is important that sponsors and IRBs consider whether changes made to a
98 legally marketed IVD, including changes to IVD labeling, result in it being investigational
99 and, if so, subject to the IDE regulation. For example, changes to a cleared or approved IVD
100 that would identify a new patient population, new specimen type, or both, would render the
101 IVD investigational for the new intended use. An illustration of this would be a test
102 approved for measuring HER2 levels *in breast cancer patients* for the purposes of
103 determining if the patient should receive treatment with trastuzumab would be considered
104 investigational in a clinical trial when used for measuring HER2 levels *in lung cancer*
105 *patients* for the purposes of determining if the patient should receive treatment with
106 trastuzumab).¹⁵ Legally marketed IVDs that are used in therapeutic product trials in
107 accordance with the intended use and indications for use for which they were cleared or
108 approved (and that have not been modified) are not considered to be investigational, and
109 hence are not subject to the IDE regulation.

110 **B. IDE Regulation and Investigational IVD Risk in**
111 **Investigations**

112 Investigational devices are subject to the IDE regulation. The regulatory requirements for
113 an investigational IVD are determined by the risk posed to subjects by use of that IVD.
114 The IDE regulation describes three categories of device studies: significant risk (SR)
115 studies, non-significant risk (NSR) studies, and exempt studies. It is important for
116 sponsors and IRBs to understand the differences between these categories and
117 appropriately evaluate the risks associated with the use of investigational IVDs in
118 therapeutic product trials. Each investigational IVD (including those that are legally
119 marketed for a different intended use and those that are legally marketed but significantly
120 modified) should be assessed to determine if it is SR, NSR, or exempt.

121 The intended use of an investigational IVD in a therapeutic product trial, which is needed
122 to determine if the IVD is SR, NSR, or exempt, depends upon how that IVD is
123 incorporated in the clinical protocol, including how test results will drive treatment
124 assignment or otherwise influence the clinical management of study subjects. When
125 describing the intended use of an investigational IVD in a study risk determination Q-
126 submission (see section III.H for additional information on submitting a study risk

¹³ For purposes of this document, a legally marketed IVD is one that is approved, cleared, or Class I or Class II exempt. For purposes of this document, cleared or approved IVDs include those that were granted *de novo* classification.

¹⁴ See Appendix for a description of “intended use.”

¹⁵ Another example of an investigational use is modifying the use of the device such that quantitative results can be obtained rather than qualitative results, e.g., use in titration studies.

Contains Nonbinding Recommendations

Draft – Not for Implementation

127 determination Q-submission utilizing the Q-Submission process) or an investigational
128 plan contained in an IDE submission (21 CFR 812.25(a)), the types of information
129 discussed in the “Intended Use” section of this guidance’s Appendix should be addressed.

130 The following discussion of the nature of risks is specific to device studies under the IDE
131 regulation and is not intended to inform FDA’s risk evaluation in other contexts,
132 including FDA’s assessment of potential risk during FDA’s classification of IVDs.
133 Furthermore, the evaluation of risk, or the determination of exemption under the IDE
134 regulation, for investigational IVDs in therapeutic product trials is independent of the
135 determination of whether an IND is required for that same trial. For a general discussion
136 of this topic, please refer to the guidance entitled "Significant Risk and Nonsignificant
137 Risk Medical Device Studies"
138 (<http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126418.pdf>).
139

140 **1) Significant Risk (SR) Devices**

141 As defined in 21 CFR 812.3(m), a significant risk (SR) device means an investigational
142 device that:

143 (1) Is intended as an implant and presents a potential for serious risk to the health,
144 safety, or welfare of a subject;

145 (2) Is purported or represented to be for a use in supporting or sustaining human life
146 and presents a potential for serious risk to the health, safety, or welfare of a subject;

147 (3) Is for a use of substantial importance in diagnosing, curing, mitigating, or treating
148 disease, or otherwise preventing impairment of human health and presents a potential
149 for serious risk to the health, safety, or welfare of a subject; or

150 (4) Otherwise presents a potential for serious risk to the health, safety, or welfare of a
151 subject.

152 Sections 812.3(m)(3) and (4) are especially relevant to the use of investigational IVDs in
153 therapeutic product trials as described in this guidance. Incorrect test results can present
154 significant risk when they lead to misdiagnosis and/or mismanagement of subjects’ care. For
155 example, if the treatment is a drug that has significant toxicity and efficacy is expected only
156 in the marker-positive population, false positive test results may lead subjects without the
157 marker to be treated with the drug, and therefore risk experiencing serious adverse events
158 without any expectation of benefit. Note that under 21 CFR 812.3(m), the relevant
159 consideration is whether there is a potential for serious risk, but not the likelihood for serious
160 harm occurring. Invasive sampling¹⁶ (e.g., certain biopsies or sampling procedures) may also
161 introduce significant risk, even if the selection of therapy is not guided by results from the
162 investigational IVD.

¹⁶ See 21 CFR 812.2(c)(3)(ii); see also 21 CFR 812.3(k) for a definition of *noninvasive*.

Contains Nonbinding Recommendations

Draft – Not for Implementation

163

164 For a more detailed discussion on the subject of risk assessment, see section III.C in this
165 guidance.

166

167

2) Non-Significant Risk (NSR) Devices

168

169 FDA may consider certain non-exempt investigational IVDs in a therapeutic product trial to
170 present risks that are not considered significant (21 CFR 812.3(m)). In such cases, the
171 investigational IVD is considered to be non-significant risk (NSR).

172

173 If an investigational IVD in a therapeutic product trial is considered to be NSR, the trial is
174 considered to have an approved IDE, i.e., the sponsor does not need to submit an IDE
175 application and obtain FDA approval before starting the trial, if the sponsor complies with
176 the abbreviated IDE requirements described in 21 CFR 812.2(b), including obtaining IRB
177 approval of the trial and complying with the informed consent requirements under 21 CFR
178 part 50.¹⁷

179

180 There is no requirement to inform the relevant FDA device review Center (whether the
181 Center for Devices and Radiological Health (CDRH) or the Center for Biologics Evaluation
182 and Research (CBER)) of NSR studies, even when the device is used in a therapeutic product
183 study.¹⁸ When the sponsor determines that an investigational IVD used in a therapeutic
184 product trial is NSR and submits the investigation to the IRB, the IRB provides initial
185 review, approval if appropriate, and continuing review of the trial (see Section III.D of this
186 guidance). If information becomes available that the investigational IVD represents an
187 unreasonable risk to the safety of the subjects (for example, the information indicates that
188 significant harm has been incurred as a result of using an investigational IVD that was
189 considered NSR in a therapeutic product trial, even if the IRB concurred with the sponsor
190 that the device in question was NSR), FDA may place a clinical hold on the trial,¹⁹ and may
191 require submission and approval of an IDE prior to continuation of the trial (21 CFR
192 812.20(a)).

¹⁷ However, if FDA notifies the sponsor that the investigational IVD is significant risk, the sponsor must submit an IDE application to FDA and obtain approval before starting the investigation (21 CFR 812.2(b) and 812.20(a)).

¹⁸ However, the sponsor must notify the applicable FDA device review Center (CDRH or CBER) of any unanticipated adverse device effect, withdrawal of IRB approval, device recall or disposition, failure to obtain informed consent, or when otherwise directed by the IRB or FDA (21 CFR 812.150). All records associated with an NSR study are subject to inspection by FDA, particularly if the data collected in the investigation are used to support a subsequent U.S. device marketing application (21 CFR 812.145).

¹⁹ The Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. No. 112-144, 126 Stat. 1054), enacted in 2012, amended section 520(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding a new paragraph (8) that gave FDA explicit authority to place a study on “clinical hold” when the device involved represents an unreasonable risk to the safety of the persons who are the subjects of the clinical investigation and for such other reasons as FDA may by regulation establish.

193

3) IDE Exempt Investigations

194

Trials involving investigational IVDs are exempt from most requirements found under the IDE regulation if they meet the criteria outlined in 21 CFR 812.2(c).²⁰ These trials are considered “exempted investigations.” Most pertinent to this guidance, to be an exempted investigation under 21 CFR 812.2(c)(3), the investigational IVD used in the study must be labeled in accordance with 21 CFR 809.10(c) and the testing (i) must be noninvasive, (ii) must not require an invasive sampling procedure that presents significant risk, (iii) must not by design or intention introduce energy into a subject, and (iv) must not be used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.²¹ Under 21 CFR 809.10(c)(2)(ii), for such a device, when being shipped or delivered for product testing prior to full commercial marketing, all labeling must bear the following statement, prominently placed: “For Investigational Use Only. The performance characteristics of this product have not been established.”

206

207

Even if a device investigation is exempt under 21 CFR 812.2(c) from most requirements of the IDE regulation, such studies are subject to applicable requirements under 21 CFR 812.119 (disqualification of a clinical investigator), 21 CFR Part 50 (informed consent) and 21 CFR Part 56 (IRB).^{22,23} For more information on exempted investigational IVD investigations, see the guidance entitled “In Vitro Diagnostic Device Studies – Frequently Asked Questions”

213

(<https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM071230.pdf>).

214

215

C. Evaluating Whether an Investigational IVD Used in a Clinical Investigation of a Therapeutic Product is Significant Risk

216

217

218

Because the regulatory requirements for use of a non-exempt investigational IVD differ based on the risk of its use, sponsors should assess IVD risk during the planning phase of a clinical investigation. In large part, the risk will depend on the clinical consequences of erroneous or inaccurate results from the IVD (e.g., false positives or false negatives). Risk determinations should take into consideration factors that may be unique to each trial and the investigational therapeutic product and investigational IVD used.

219

220

221

222

223

²⁰ Sponsors of investigational IVDs that are exempt under 21 CFR 812.2(c) must comply with applicable requirements under 21 CFR 809.10(c), 812.119, Part 50, and Part 56.

²¹ We consider “diagnosis” here to mean diagnosis of a disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae (21 CFR 809.3(a)).

²² Sponsors and IRBs who have questions about these requirements may contact Elaine Katrivanos (Elaine.Katrivanos@fda.hhs.gov), Division of Program Operations and Management, Office of *In Vitro* Diagnostics and Radiological Health.

²³ For questions related to a CBER-regulated IVD, please contact the Regulatory Project Manager (RPM) in the CBER Office where your product will be reviewed. If you don’t know or are unsure of whom to contact, please contact CBER’s Office of Communication, Outreach and Development (OCOD) as listed on the title page of this guidance.

Contains Nonbinding Recommendations

Draft – Not for Implementation

224

225 The sections below present questions to help sponsors and IRBs evaluate critical factors
226 when making risk determinations for investigational IVDs in therapeutic product trials and
227 describe how clinical trial designs generally affect the risk of investigational IVD use.

228

229

1) Factors to Consider in Making a Risk Determination

230

231

232

233

234

235

This section presents key questions that sponsors and IRBs should consider when assessing the risk of investigational IVD use in a therapeutic product study. These questions are focused on considerations regarding how results from the IVD will be used, the potential consequences of such use, and a number of other factors pertaining to the specific circumstances of the study. Answers to these questions will assist sponsors and IRBs in assessing whether the trial involves a significant risk device as defined in 21 CFR 812.3(m).

236

237

238

239

a. Will use of the results from an investigational IVD lead to some study subjects foregoing or delaying a treatment that is known to be effective?

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

When the result from an investigational IVD directs subjects to an investigational therapeutic product, the availability of alternative therapies and the nature of those alternatives may influence the level of risk to the subject from an erroneous result. For example, in an investigation for a population that has no other treatment options, has exhausted all other treatment options, or for which standard of care provides only marginal benefit, the potential harm caused by an erroneous result from the investigational IVD use may be lower, because the investigational therapeutic product may not present greater risks than the alternatives available to the subject. Likewise, if treatment with the investigational therapeutic product will not interfere with the likely effectiveness of later treatment with a known effective therapy (i.e., a delay in receiving the known effective therapy will not irreversibly degrade the condition of the subject), the risk of an erroneous investigational IVD result may be lower. If, however, the standard of care or other alternatives are reasonably effective, or a delay in receiving known effective therapy would irreversibly degrade the condition of the subject, then the potential harm caused by an erroneous investigational IVD result may be greater.

257

258

259

260

261

262

263

b. Will use of the results from an investigational IVD expose study subjects to safety risks (e.g., adverse events from the investigational therapeutic product) that exceed the risks encountered with the control arm therapy or non-trial standard of care?

264

265

266

267

The risk(s) of the investigational therapeutic product should be considered in assessing the risk of investigational IVD use. When a drug has minimal side effects, for instance, the risk associated with use of the investigational IVD for enrollment or assignment to treatment arms will generally be lower because an

Contains Nonbinding Recommendations

Draft – Not for Implementation

268 erroneous test result would not be expected to cause serious harm. However, in a
269 study of an investigational therapeutic product with significant toxicity, the risk
270 associated with investigational IVD use will generally be greater because an
271 erroneous test result could unnecessarily expose a subject to the therapeutic
272 product’s toxicity.

273

274 **c. Is it likely, based on existing knowledge about the relationship**
275 **between the biomarker and the investigational therapeutic**
276 **product, that incorrect results from the investigational IVD would**
277 **present a potential for serious risk to study subjects?**

278

279 Existing knowledge about the relationship of the result obtained from the
280 investigational IVD and the potential safety and efficacy of the investigational
281 therapeutic product should be considered independently of the answers to
282 questions posed in sections III.C.1.a and b. For instance, if there is strong (e.g.,
283 clinical) evidence that an investigational therapeutic product with serious side
284 effects may be effective only in a marker-positive population, then an
285 investigational IVD used to identify marker-positive subjects is likely to be of
286 higher risk, regardless of the relative safety and efficacy of the standard of care
287 or alternative therapies.

288

289 A determination that the investigational therapeutic product should be restricted
290 to a test-defined population may rely on preclinical studies. However, evidence
291 needed to define a biomarker-positive or –negative population is oftentimes
292 obtained during early clinical trials or in the course of an ongoing trial. For this
293 reason, an investigational IVD that is initially NSR (e.g., used for stratification)
294 could become SR in a later phase investigation of the same therapeutic product,
295 or even in the middle of a particular trial. Surveillance and changing risk is
296 discussed in section III.C.3 below.

297

298 **d. Does use of the investigational IVD require invasive sampling**
299 **that is not part of standard of care?**

300

301 If invasive sampling is used to collect samples for testing with the investigational
302 IVD, and that sampling is not part of the standard of care (for example, if extra
303 biopsies of a tumor or an additional surgical procedure to obtain a specimen for
304 testing is required), then the IVD may be SR, regardless of the risks associated
305 with erroneous results.

306

307 **2) Investigational IVD Risk and the Design of Clinical**
308 **Investigations for Therapeutic Products**

309 This section describes some intended uses for investigational IVDs in the context of some
310 commonly used therapeutic product trial designs. To assess risk, it is important to understand
311 how the intended use of the investigational IVD affects trial subjects’ medical treatment.

Contains Nonbinding Recommendations

Draft – Not for Implementation

312

313 Note that the risks associated with the trial designs and other uses described in the examples
314 below are presented without reference to other information that may affect the overall risk
315 from an erroneous result. As discussed in the previous section (section III.C.1), predicted
316 side effects of the investigational therapeutic product and other factors should also be taken
317 into account when making a final risk determination.

318

319 • **Study enrollment.** Investigational IVDs can be used to identify subjects for enrollment
320 eligibility. The goal is usually to identify for inclusion those subjects most likely to
321 benefit from therapy (efficacy), or to identify for exclusion those subjects most likely to
322 suffer toxicity without significant benefit. Misclassification of subjects due to erroneous
323 investigational IVD results can lead to treatment that might unnecessarily expose them to
324 toxicities or suboptimal treatment.

325

326 • **Predicting serious adverse reactions.** An investigational IVD can be used to identify
327 study subjects likely to be at increased risk for serious adverse reactions as a result of
328 treatment with an investigational therapeutic product, and who, thus, should be subjected
329 to additional or different monitoring or therapeutic procedures. Similarly, the
330 investigational IVD may be used to identify subjects at decreased risk for adverse
331 reactions, and thus results from that IVD may justify reduced monitoring. This use of the
332 IVD, given its role in predicting risk for serious adverse reactions to the investigational
333 therapeutic product, is potentially of higher risk due to the probable harm that may be
334 incurred from acting on incorrect test results. The potential use of an investigational IVD
335 to predict the risk of serious adverse reactions may be identified while the trial of an
336 investigational therapeutic product is already underway. This may lead to a change in the
337 use of the investigational IVD and its associated risk from lower risk at the start of the
338 trial to higher risk during the course of the trial (see section III.C.3 below).

339

340 • **Dosing.** Safety and efficacy of a therapeutic product is often closely related to the dose
341 administered if that product has a narrow therapeutic window and/or has harmful effects
342 outside of the efficacy window. When over- or under-dosing may pose serious risks and
343 an investigational IVD is used to determine the dose a study subject should receive, that
344 use is likely to be of higher risk.

345

346 • **Monitoring.** An investigational IVD generally has higher risk when it is used to
347 determine response to an investigational therapeutic product for the purpose of adjusting
348 that treatment (e.g., schedule, dose, discontinuation) to maintain an appropriate
349 therapeutic or safety margin.

350

351 • **Assigning subjects to study arms.** An investigational IVD can be used to assign
352 enrolled subjects to a particular study arm. The risks associated with assignment depend
353 on the study design (some examples noted below). However, if a study design involves a
354 combination of different trial designs, the investigational IVD will be of higher risk if its
355 use is of high risk within any particular component of the trial.

356

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 357
- 358
- 359
- 360
- 361
- 362
- 363
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371
- 372
- 373
- 374
- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382
- 383
- 384
- 385
- 386
- 387
- 388
- 389
- 390
- A stratification study design utilizes an investigational IVD result to classify subjects into test-positive or test-negative subgroups, followed by randomization to the investigational therapeutic product or control group within each of the subgroups. When each subject has an equal chance of being in the investigational therapeutic product or control group, the investigational IVD is generally of lower risk because its use does not determine treatment selection. In some cases, the result contributes to a probability of being assigned to a particular treatment, but is not the sole determinant. In such cases, the degree of risk related to investigational IVD use will depend on the degree to which the result contributes to that probability.
 - Adaptive study designs typically advance in stages, with inclusion/exclusion criteria or methodologies for assigning study subjects to treatment arms in later stages based on the outcome of earlier stages.²⁴ In such trials, early use of the investigational IVD may be NSR; however, use of the IVD in subsequent phases may be different and may present additional risk. When investigational IVD use becomes SR in a later stage of an adaptive trial, FDA approval of an IDE application will be required for continued use of the investigational IVD in the trial (see section III.C.3 below).
 - **Retrospective studies.** Retrospective studies involve the analysis of specimens after subjects are enrolled in the trial or the trial is complete. In most cases, if the investigational IVD result does not influence treatment, that IVD would be considered lower risk and may be exempt from most IDE regulation requirements if the criteria in 21 CFR 812.2(c)(3) are met (see section III.B.3 above). Prospective retrospective studies, where specimens are collected expressly for the purpose of retrospective analysis, would carry the risk associated with specimen collection occurring outside of standard patient care.
- Note that certain trial features do not inherently influence an investigational IVD risk determination. Among these are the size and the phase of the trial, the “line” of therapy proposed for the investigational therapeutic product, and the potential access of patients to other trials.

²⁴ For more discussion of adaptive study designs, see the guidance entitled “Adaptive Designs for Medical Device Clinical Studies” (<https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM446729.pdf>) and the draft guidance entitled “Adaptive Design Clinical Trials for Drugs and Biologics” (<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf>) (This draft guidance represents FDA’s proposed approach on this topic. When final, this guidance will represent FDA’s current thinking on this topic.).

391 **3) How Investigational IVD Risk May Change During the Course**
392 **of a Clinical Investigation**

393 When an investigational IVD is NSR at the beginning of a clinical investigation but becomes
394 SR at a later stage, or when a SR investigational IVD is introduced into a clinical
395 investigation, FDA approval of an IDE application, in accordance with 21 CFR 812.20(a)(2)
396 and 21 CFR 812.30(a), is required prior to use of the SR investigational IVD in the clinical
397 investigation. There are several ways in which an investigational IVD may be introduced into
398 a clinical investigation or an investigational IVD's use may change during the course of a
399 clinical trial.

400

401 • Safety and outcomes data, and other information gathered during the trial may change
402 the risk of the investigational IVD. For example, if results from early subjects in the
403 trial indicate more severe side effects or less improvement in a biomarker-positive
404 population than expected, the assessment of risk from use of an investigational IVD
405 to detect that biomarker may change.

406

407 • Adaptive clinical trial designs that incorporate pre-planned and conditional alterations
408 in trial conduct may change the use of an investigational IVD as the trial progresses.
409 Risk posed by altered use of the IVD should be considered.

410

411 • A new or amended study protocol for an existing investigational new drug application
412 (IND) may introduce or alter the risk of an investigational IVD. For instance, a Phase
413 1 trial may not include an IVD or it may include an IDE exempt or a NSR IVD.
414 However, a later Phase 2 trial conducted under the same IND may add a SR device or
415 may change the use of an investigational IVD in such a way as to make the IVD SR.
416 In such a case, the sponsor would be required to submit an IDE application to FDA in
417 accordance with 21 CFR 812.20; the investigational IVD could not be used in the
418 Phase 2 trial until FDA approves the IDE application (21 CFR 812.20(a)(2) and
419 812.30(a)).

420

421 Ongoing surveillance during a clinical investigation is recommended to monitor the risk of
422 the investigational IVD. For a SR investigation, the timing of an IDE application is at the
423 sponsor's discretion and should be planned to allow sufficient time for FDA review before
424 the use of the SR investigational IVD in the clinical investigation. FDA recommends
425 interacting with the applicable Center (CDRH or CBER) via the Q-Submission process (see
426 section III.H) prior to initiating the first stage of the trial. This interaction may facilitate FDA
427 review of a future IDE application if required and may provide the sponsor with greater
428 predictability in regard to the IDE process.

429 **D. Recommendations for IRBs and Sponsors in**
430 **Evaluating Investigational IVDs in the Context of Clinical**
431 **Investigations for Therapeutic Products**

432

Contains Nonbinding Recommendations

Draft – Not for Implementation

433 Each U.S. site that performs testing using the investigational IVD is considered a study site.
434 Whether a trial involves only one site or many sites, it is the responsibility of the trial sponsor
435 to ensure that IRB review and approval are obtained (21 CFR 812.40).

436
437 Each reviewing IRB must, as part of its review of the clinical investigation, consider the
438 sponsor's risk determination of the investigational IVD (21 CFR 56.108, 56.111,
439 812.2(b)(1)(ii), 812.62, and 812.66). If a sponsor and its IRB cannot agree on the level of risk
440 presented by the investigational IVD, the sponsor may request a study risk determination
441 from FDA through the Q-Submission process (see section III.H).

442 If the IRB concurs with a sponsor's NSR determination and approves the investigation, and
443 the sponsor complies with the abbreviated requirements in 21 CFR 812.2(b)(1), the sponsor
444 is considered to have an approved IDE for use of the investigational IVD in the therapeutic
445 product trial, unless FDA has notified the sponsor under 21 CFR 812.20(a) that approval of
446 an IDE application is required. Failure of a sponsor and an IRB to recognize or correctly
447 assess the risks of use of an investigational IVD in a therapeutic product trial may deprive the
448 study subjects of the additional protections associated with significant risk device
449 investigations. In addition to other IDE requirements, a significant risk device study entails
450 FDA evaluation of the investigational IVD to determine, among other things, whether the
451 IVD has been adequately validated for its use in the study. For this reason, it is important for
452 IRBs to be aware of how investigational IVDs are used and the risks associated with their use
453 in the context of therapeutic product trials.

454 The information described below is intended to provide assistance to sponsors and IRBs in
455 understanding FDA's regulations, and to aid in the development of a risk assessment process
456 for investigational IVDs intended for use in therapeutic product trials.

457

458 **1) Information the Sponsor Should Include in Its Submission to**
459 **the IRB**

460

461 The sponsor should provide an assessment of whether or not any IVD being used in a study
462 is an investigational IVD, along with supporting information. The sponsor should also
463 provide its assessment of the investigational IVD as SR, NSR, or exempt from most
464 requirements of the IDE regulation, and provide a rationale for the assessment.²⁵ Note that
465 this should be done even if the forms provided by the IRB to the sponsor do not specifically
466 request such information. If the IRB determines that the investigational IVD is SR and
467 notifies the sponsor of such determination, then the sponsor may either seek a study risk
468 determination from FDA (if the sponsor disagrees with the IRB's determination) or submit
469 an IDE application to FDA and comply with other applicable regulatory requirements in the
470 IDE regulation.²⁶

²⁵ Under 21 CFR 812.2(b)(1)(ii), if the sponsor believes its investigational device is NSR, the sponsor must present the IRB with a brief explanation of why the device is NSR.

²⁶ Under 21 CFR 812.150(b)(9), if the IRB disagrees with an NSR determination by the sponsor and determines that the device poses a significant risk, the sponsor must report this finding to the FDA within five working days.

Contains Nonbinding Recommendations

Draft – Not for Implementation

471

472 In reviewing a clinical investigation, an IRB considers whether the criteria in 21 CFR 56.111
473 are met, including that the risks to subjects are minimized and are reasonable in relation to
474 the anticipated benefits, if any, to subjects, and the importance of the knowledge that may be
475 expected to result. So that IRBs may make such a determination, in the submission of a
476 therapeutic product trial to an IRB, a sponsor should identify each investigational IVD and its
477 use in the trial.²⁷

478

479

2) Recommendations for Review Questions for IRBs

480 In order to carry out its obligations under 21 CFR Part 56, including that information given to
481 subjects as part of informed consent is in accordance with 21 CFR 50.25 (as required by 21
482 CFR 56.109(b)) and that a clinical investigation meets the criteria for approval in 21 CFR
483 56.111, IRBs should assess the risks of use of proposed investigational IVDs in all
484 therapeutic product trials. IRBs should request follow-up information if they believe that the
485 sponsor did not identify or adequately describe the use of an investigational IVD and its
486 associated risks in such trials.

487

488 To correctly identify whether an investigational IVD is used in a study, and to assess the
489 risks of use of an investigational IVD in such study, FDA recommends that IRBs consider
490 the following questions when reviewing applications for therapeutic product trials:

491

492 1) Are one or more IVDs being used in this study? If so, the answers to the following
493 questions should be assessed separately for each IVD.

494 2) Is the IVD investigational?

495 a. Is the IVD legally marketed (see footnote 13)? If not, its use in the clinical trial
496 should be considered investigational.

497 b. If the IVD is legally marketed, does the use of the IVD in the therapeutic product
498 study represent a new use (see section III.A.)? A new use for a cleared or
499 approved IVD will make that device investigational and subject to the IDE
500 regulation. New uses may involve use of the IVD on patient populations for which
501 it was not cleared or approved, or use in the same patient population but with a
502 different specimen type or with a different therapeutic product than for which it
503 was cleared or approved. Other modifications to a cleared or approved IVD,
504 including changes to the instructions for use, may also render it investigational and
505 subject to the IDE regulation.

506 If the IVD is investigational:

²⁷ Under 21 CFR 50.25(a), the informed consent form must include, among other things, a description of any experimental procedures and of any reasonably foreseeable risks or discomforts to the subject. Therefore, the informed consent form must identify investigational IVD use and the risks associated with that use in the clinical investigation. Description and acceptance of investigational IVD risk does not constitute mitigation of that risk.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 507 3) Does it meet the exemption criteria under 21 CFR 812.2(c)? For example, does it meet
508 the criteria in 21 CFR 812.2(c)(3), which are specific to diagnostic devices? Note that
509 even if it is exempt under 21 CFR 812.2(c), sponsors must comply with applicable
510 requirements under 21 CFR 809.10(c), 812.119, Part 50, and Part 56..
- 511 4) If not exempt under 21 CFR 812.2(c), what are the risks of investigational IVD use in
512 this investigation (see section III.C)? In particular:
- 513 a. Would inaccurate results from use of the investigational IVD present a potential
514 for serious risk to the health, safety, or welfare of a subject? Consideration of the
515 trial's design (see section III.C.2 above) may help in addressing the key questions
516 about significant risk that are set forth in section III.C.1. Examples of specific
517 questions to consider are:
- 518 1. Does the investigational IVD determine whether a subject is enrolled in a
519 study, or to which treatment arm within that study a subject will be assigned? If
520 so, what are the consequences of an incorrect investigational IVD result?
- 521 2. Will the investigational IVD be used for subject monitoring or adjusting
522 dosage? Again, the risk associated with erroneous investigational IVD results
523 should be considered.
- 524 b. Does specimen collection for use of the investigational IVD present a potential for
525 serious risk to the health, safety, or welfare of a subject? If use of the
526 investigational IVD involves invasive procedures for the subject that would not
527 normally be performed as part of standard of care or patient management, then it
528 may be considered SR.
- 529 5) Is an IDE application required for the investigation? It is important to understand that
530 compliance with the IND regulation does not exempt the investigation from the IDE
531 regulation (see sections III.E - III.G).
- 532 6) If an IDE application is required, what is the status of the IDE application? While an
533 IRB is not involved in the review of an IDE application, the IRB may wish to be made
534 aware of FDA's comments and decision on the IDE application.
- 535 7) Do informed consent documents clearly explain the investigational nature of the IVD
536 and its risks (e.g., the risks of inaccurate test results)? In accordance with 21 CFR
537 50.25(a)(1) and (2), informed consent documents must identify any procedures which
538 are experimental and provide a description of any reasonably foreseeable risks or
539 discomforts to the subjects. Thus, the informed consent documents for the types of
540 investigations discussed in this guidance must describe any reasonably foreseeable risks
541 or discomforts associated with the investigational therapeutic product and the fact that
542 an investigational IVD would be used along with any reasonably foreseeable risks or
543 discomforts associated with that use. For the investigational IVD, these risks include
544 the risks associated with inaccurate results (in the context of IVD use in the study), and
545 the risks associated with specimen collection and use as part of the study.

546 **3) When Can a Sponsor Begin a Therapeutic Product Trial**
547 **Involving Use of an Investigational IVD?**

548 In addition to IRB approval, it is important for sponsors to understand that even if a
549 therapeutic product trial is permitted under the IND regulation, or is exempt from the
550 requirements of the IND regulation under 21 CFR 312.2(b), the sponsor must still have an
551 IDE that is approved or approved with conditions by the FDA if the trial includes a SR
552 investigational IVD.

553
554 As explained in FDA’s guidance entitled “FDA Decisions for Investigational Device
555 Exemption Clinical Investigations”
556 ([www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/
557 ucm279107.pdf](http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm279107.pdf)), approval with conditions for an IDE indicates that: (i) FDA believes the
558 sponsor has provided sufficient data to support initiation of subject enrollment in a clinical
559 investigation; (ii) there are no subject protection concerns that preclude initiation of subject
560 enrollment; (iii) there *are* additional conditions that must be met to address certain
561 outstanding issues; and (iv) the investigation may proceed, but the additional conditions are
562 to be fulfilled within 45 days of the date of FDA’s decision letter. FDA recommends that
563 IRBs ensure that any investigation incorporating an SR investigational IVD has an FDA-
564 approved or conditionally approved IDE by obtaining a copy of FDA’s IDE approval letter
565 from the sponsor of the investigation.

566
567 Sponsors and IRBs should be aware of protocol amendments that may change subject
568 monitoring as outlined in 21 CFR 312.30(b)(1)(iii).²⁸ They should also be aware of other
569 modifications to the protocol that alter the investigational IVD risk from NSR to SR, or that
570 add the use of an SR investigational IVD to a therapeutic product trial which originally did
571 not involve any investigational IVD, or involved the use of an investigational IVD that met
572 the criteria for exemption under 21 CFR 812.2(c)(3), or involved the use of an NSR
573 investigational device. Attention to such protocol amendments by IRBs is critical in
574 protecting study subjects (see section III.C.3) Changes that introduce a SR investigational
575 IVD to the trial will require FDA approval of a new IDE or approval of a supplement to an
576 existing IDE independent of any amendments to an existing IND (21 CFR 812.20).

577 **E. Common Questions about Investigational IVD Use in**
578 **Clinical Investigations of Therapeutic Products and**
579 **Compliance with the IDE Regulation**

580 The IDE regulation applies to *all* clinical investigations of devices to determine safety and
581 effectiveness (see section III.A) except as provided in 21 CFR 812.2(c) (21 CFR 812.2(a)).
582 FDA has identified several situations in which sponsors and IRBs had questions as to
583 whether an IDE was required. These include:

²⁸ 21 CFR 312.30(b)(1)(iii) requires the submission of a protocol amendment for “[t]he addition of a new test or procedure that is intended to improve monitoring for, or reduce the risk of, a side effect or adverse event; or the dropping of a test intended to monitor safety.”

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 584 • Use of an investigational IVD in a therapeutic product trial that was exempt from the
585 IND regulation. Even if the therapeutic product(s) in the trial is/are exempt from the
586 requirements of 21 CFR Part 312 under 21 CFR 312.2(b), the investigational IVD in
587 the trial is subject to the IDE regulation (21 CFR Part 812). If the investigational IVD
588 does not meet the exemption criteria under 21 CFR 812.2(c), then a risk assessment
589 should be conducted to determine whether the IVD is NSR or SR. If the
590 investigational IVD is SR, then in accordance with 21 CFR 812.42, a sponsor shall
591 not begin an investigation or part of an investigation involving the IVD until FDA has
592 approved an IDE application.
- 593 • Use of an investigational IVD without intent to commercialize. If the investigation
594 uses an investigational IVD for directing the management of subjects but the IVD
595 manufacturer does not intend to seek FDA clearance or approval for the commercial
596 distribution of the IVD, the IDE regulation may still apply, as 21 CFR 812.2(a) states
597 that Part 812 applies to all clinical investigations of devices to determine safety and
598 effectiveness²⁹ except as provided in 21 CFR 812.2(c), which addresses investigations
599 exempted from most of the IDE regulation.

600 **F. Inclusion of Investigational IVD Information in an**
601 **IND**

602 Increasingly, the use of diagnostic tests for markers of interest in therapeutic treatment
603 selection in protocols submitted to therapeutic product INDs has necessitated consultation
604 between the device review Center (CDRH or CBER) and the therapeutic product review
605 Center (CDER or CBER). Sponsors should be aware that all investigational IVDs used in
606 therapeutic product trials are also subject to the IDE regulation (21 CFR Part 812), and may
607 also require the submission of a separate IDE application if determined to be SR. A
608 therapeutic product trial that also incorporates the use of an SR investigational IVD may not
609 be initiated without an approved IDE application.³⁰ Parts of the therapeutic product trial
610 unrelated to the investigational IVD may still proceed, however, unless the trial is placed on
611 clinical hold by the therapeutic product review Center.

612
613 Although studies with NSR investigational IVDs do not require the submission of an IDE,
614 they must still comply with the abbreviated IDE requirements described in 21 CFR 812.2(b).

²⁹ See section III.A for further discussion.

³⁰ When an approved IVD is used to guide the therapeutic management of subjects in a clinical trial of a new therapeutic product (e.g., a HER2 test that is approved for use with trastuzumab is used to guide the therapeutic management of subjects in a clinical trial of a new breast cancer drug), generally the use of the IVD would be considered investigational (see section III.A). However, for such IVDs, FDA does not intend to examine whether they comply with the requirement for IDE approval under the FD&C Act and 21 CFR Part 812 when IRB approval is obtained and maintained for the investigation using such IVD, the investigation meets the abbreviated requirements under 21 CFR 812.2(b)(1)(i), (iii)-(vii), and assurance is provided to the IND that the IVD is used with the new therapeutic product in accordance with the instructions for use (IFU) that are provided in the device's approved labeling. Assurance of adherence to the IFU should minimally address the intent-to-test criteria (e.g., disease type [such as lung cancer, colon cancer], specimen type [such as plasma, serum, tissue], and specimen adequacy), the test methodology, and the classification criteria (i.e., cutoff, if used).

Contains Nonbinding Recommendations

Draft – Not for Implementation

615 In addition, under the IND regulation, clinical protocols for INDs must contain a description
616 of laboratory tests used to monitor the effects of the drug in human subjects and to minimize
617 risk (21 CFR 312.23(a)(6)(iii)(g)). Further, FDA may request that the sponsor submit in the
618 IND other relevant information concerning the IVD(s) used in the trial as needed (21 CFR
619 312.23(a)(10)(iv),(11)). For instance, the therapeutic product review Center (CDER or
620 CBER) may request submission of IVD data, including performance data, to an IND should
621 such information be needed to assess the clinical trial as a part of the IND review.

G. Managing IDEs and INDs for the Same Study

623 To simplify the application process, the IDE submission for a therapeutic product trial that is
624 under an IND should cite the corresponding IND number. IDEs and INDs may also cross-
625 reference each other through a letter of authorization (LOA) or, in cases where either an IND
626 or IDE is not required, information about the non-submitted investigational product may be
627 provided through use of a master file.³¹ Master files allow one party to submit information
628 for confidential review by FDA without granting access to other parties. For instance, if the
629 manufacturer of the investigational IVD wishes to refer to confidential information about an
630 investigational drug product to which it does not have access, the therapeutic product
631 manufacturer can submit a master file containing that information and authorize the IVD
632 manufacturer to reference it. FDA will then review the information in the master file as part
633 of its review of the IDE for the investigational IVD. Similarly, an IVD manufacturer may
634 submit a master file and authorize a therapeutic product manufacturer to reference that file,
635 so that the confidential information about the investigational IVD can be included in FDA's
636 review of the therapeutic product IND. In cases in which the relevant confidential
637 information has been submitted in another regulatory submission, such as an IND or an IDE,
638 the owner of the submission may simply provide the third party an LOA to reference specific
639 sections of the regulatory submission. The LOA may grant the FDA either the *right to*
640 *reference* or the *right to reference and discuss* the information in the regulatory submission
641 with the third party.

642
643 An IND and IDE may be held by the same sponsor or each may be held by different sponsors
644 representing different entities (e.g., a pharmaceutical company and an IVD company). The
645 investigation conducted under the IND is subject to clinical hold under 21 CFR 312.42.³² For
646 example, CDER may place an investigation on clinical hold under 21 CFR 312.42(b)(1)(i) or
647 (b)(2)(i) if the agency determines that the investigation places subjects at an unreasonable
648 and significant risk of illness or injury. For example, this determination could be made
649 because an investigational IVD used to identify subjects for inclusion in the clinical trial of

³¹ For more information, see Introduction to Master Files for Devices (MAFs) (<http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarket submissions/premarketapprovalpma/ucm142714.htm>) and Guideline for Drug Master Files (DMF) (<http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073164.htm>). For information on master files relating to biologics license applications, contact the Center responsible for review of that biological product.

³² This is in addition to the authority granted under FDASIA to place investigations subject to the IDE regulation on clinical hold. See footnote 19, above.

Contains Nonbinding Recommendations

Draft – Not for Implementation

650 an investigational therapeutic product with significant toxicity was deficient and therefore
651 might not reliably select subjects. Regardless of whether the IND and IDE are held by the
652 same or different sponsors, sponsors should understand the regulatory requirements
653 applicable to investigations involving both an investigational therapeutic product and an
654 investigational IVD.

655
656 An approved IDE for an investigational IVD used in a therapeutic product trial may make it
657 easier for sponsors to use that same investigational IVD for a separate therapeutic product
658 trial, as only an approved supplement to the IDE (in addition to IRB approval) may be
659 needed to commence the new trial if the IVD indication is the same or very similar (21 CFR
660 812.35).³³

661 **H. Q-Submission Meetings**

662 FDA recognizes that many factors must be considered in designing therapeutic product trials
663 that involve the use of investigational IVDs for subject selection or other purposes. As the
664 testing and therapeutic strategy is being developed, sponsors and sponsor-investigators are
665 encouraged to meet with FDA in a Q-submission meeting prior to starting the trial to discuss
666 questions about IVD risk, study design, and regulatory requirements. It is often helpful to
667 have both the IVD and the therapeutic product sponsors at these Q-Submission meetings. In
668 addition, a sponsor wishing to obtain a written study risk determination of the proposed study
669 from FDA may submit a study risk determination Q-submission. For further information, see
670 the guidance entitled “Requests for Feedback on Medical Device Submissions: The Pre-
671 Submission Program and Meetings with Food and Drug Administration Staff”
672 ([http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocu](http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm311176.pdf)
673 [ments/ucm311176.pdf](http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm311176.pdf)).

³³ Note that certain changes (e.g., a significant change to the design of the device or a change in its indication) may require approval of an IDE supplement. See 21 CFR 812.35; see also guidance entitled “Changes or Modifications During the Conduct of a Clinical Investigation” (<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm082158.pdf>).

674 **APPENDIX. Important Considerations for Sponsors**

675 This section describes important considerations for sponsors as they prepare an IDE
676 application.³⁴ When applicable, sponsors should also ensure that laboratories using the
677 investigational IVD in the investigation are compliant with the Clinical Laboratory
678 Improvement Amendments and related regulations (42 U.S.C. 263a; 42 CFR Part 493), and
679 that the investigation is compliant with all applicable statutes, regulations, and conditions of
680 IRB and/or FDA approval (21 CFR 812.30(b)(1)).

681 **A. Contents of an IDE Application**

- 682 • The contents of an IDE application are detailed in 21 CFR 812.20, 812.25, and
683 812.27. Broadly, these regulations address administrative requirements, description
684 of the IVD, prior investigations with the IVD, and the proposed investigational plan.
- 685 • For investigational IVDs that will be part of a therapeutic product trial, sponsors
686 should also address the following issues, if applicable, in IDE applications:
- 687 ○ **Investigational IVD description.** The investigational plan must include a
688 description of the investigational device (21 CFR 812.25(d)). The
689 investigational IVD description should include test principles and technology,
690 all equipment, reagents and supplies (including calibration or control
691 materials), and procedures used to conduct the test, as well as a description of
692 installation requirements and calibration parameters. All analytes detected by
693 the investigational IVD should be described. As an example, for genetic tests,
694 a list of all assayed mutations (e.g., SNPs or gene rearrangements) should be
695 supplied, as well as PCR primers and probe design, if applicable.

696
697 As part of the investigational IVD description, all necessary instruments
698 and/or software should be listed and described. Information pertaining to the
699 level of software validation that has been performed for the investigational
700 IVD will be critical in evaluating whether the investigational IVD is being
701 used appropriately in the context of the study. For investigational IVDs with
702 highly complex, multivariate algorithmic software, this may be the largest
703 portion of data submitted to support the IDE.³⁵

³⁴ For general information on IDEs, see “Guidance on IDE Policies and Procedures”
(<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080202.htm>).
Additionally, sponsors may consider various resources for information on IVD validation, for example,
Mansfield et al., Biomarkers for pharmacogenetic and pharmacogenomic studies: Locking down analytical
performance, (2007a) *Drug Discovery Today: Technologies* 4:17, and Mansfield et al., Biomarkers for
pharmacogenetic and pharmacogenomic studies: special issues in analytical performance, (2007b) *Drug
Discovery Today: Technologies* 4:21.

³⁵ For information on the type of documentation FDA will expect for device software, please reference
“Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices”
(<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089593.pdf>), issued May 11, 2005.

Contains Nonbinding Recommendations

Draft – Not for Implementation

704
705
706
707
708

709
710
711
712
713
714
715
716
717
718
719
720
721

722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739

- **Sample type, acquisition, and processing.** Descriptions of the type of specimen(s) to be tested, specimen collection, processing, storage, sample identification, and acceptance/rejection criteria should be provided.

- **Intended use.** The investigational plan must include the intended use of the investigational device (21 CFR 812.25(a)). The intended use for the investigational IVD should encompass information on the analyte to be detected and how it relates to the investigational therapeutic product; whether the IVD produces a quantitative, semi-quantitative, or qualitative result; specimen type(s); conditions for use; the condition or disease to be screened, monitored, treated, or diagnosed; the intended use population (i.e., the population that will be tested using the investigational IVD); frequency of use; and physiological basis. The intended use population should be adequately described and justified. From the standpoint of the therapeutic product trial, testing with the investigational IVD should reflect the appropriate intent-to-treat (or not-to-treat) population.

- **Description of investigational IVD cut-offs.** Cut-off values (i.e., clinical decision points) that distinguish relevant trial populations should be established for the investigational IVD. The cut-off value should represent a point where the investigational IVD’s analytical performance characteristics support reliable discrimination of the subject populations. If indeterminate (or gray) zone values will be produced, the sponsor should discuss how subjects with test values in the zone will be classified, and the use of indeterminate zone values in managing subjects in the therapeutic product trial.³⁶

- **Test performance.** The investigational IVD has demonstrated analytical validity, such that it is able to give accurate measurements from subject specimens. In the context of a therapeutic product trial, where results from the investigational IVD will be used to guide subject treatment, FDA is particularly concerned with analytical validity, including precision, reproducibility, analytic sensitivity, analytic specificity, and accuracy. Depending on the type of assay, matrix comparison, linearity, and interference may also be important.

³⁶ An example of use of a cutoff with a gray zone is the 2+ result of the immunohistochemistry HER2 tests. Reproducibility studies revealed that readers had a difficult time separating 2+ from 1+ and 3+ results. The clinical trial confirmed that fewer persons with 2+ results were having positive drug outcomes than persons with clear 3+ results, and, as a result, 2+ results were re-categorized as representing equivocal rather than positive results. To address uncertainty of values in this gray zone, clinical practice guidelines recommend retesting 2+ results with another type of test. Wolff et al., Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer, (2014) *Arch Pathol Lab Med* 138:241.

Contains Nonbinding Recommendations

Draft – Not for Implementation

740 Analytical performance around cut-off values is likely to have the largest
741 impact on subject safety. Failure to select an appropriate cutoff, or failure of
742 the investigational IVD to perform adequately around the cutoff, may result in
743 the assignment of subjects to inappropriate treatments.

744
745 The amount of information on analytical performance of an investigational
746 IVD will depend on the nature of the IVD and the therapeutic product trial in
747 which it is used. For instance, while more limited information on analytical
748 performance may be sufficient when a IVD is used in an early feasibility
749 study,³⁷ more comprehensive information on analytical performance will
750 likely be needed for a registrational or pivotal trial.³⁸

- 751
- 752 ○ **Preclinical and/or clinical information.** The preclinical and/or clinical
753 information provided should justify the subjects' exposure to the
754 investigational IVD.
 - 755
 - 756 ○ **Clinical study design.** Questions or hypotheses should be clearly stated and
757 should be addressed by a well-designed and sufficiently powered study.
 - 758
 - 759 ○ **Benefit/Risk assessment.** The IDE submission must include a risk analysis
760 that includes a justification for the investigation (21 CFR 812.25(c)). Further,
761 in reviewing an IDE application, FDA considers, among other things, whether
762 the risks to the subjects are not outweighed by the anticipated benefits to the
763 subjects and the importance of the knowledge to be gained (21 CFR
764 812.30(b)(4)). Therefore, the application should contain information on why
765 the anticipated benefits to the study subjects (or why the importance of the
766 knowledge to be gained from the trial) outweigh the risks of exposure to the
767 investigational IVD. The type, magnitude, duration, and probability of the
768 anticipated benefits should be weighed against the type, severity, duration,
769 and probability of the risks associated with the use of invasive sampling
770 techniques, as well as the potential harms that could result from an erroneous
771 test result by the investigational IVD (such as a false positive or false
772 negative). The risk of investigational IVD use in therapeutic product trials is
773 closely related to that posed by the investigational therapeutic product, and
774 therefore benefit/risk associated with the therapeutic product needs to be
775 considered in this analysis.

³⁷ For further information about early feasibility device clinical studies, see guidance entitled “Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies”

(<http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm279103.pdf>).

³⁸ Note that under 21 CFR 812.20(b)(2) and 812.27(a), the IDE application must include a complete and comprehensive report of prior investigations of the device (including clinical, animal, and lab testing).

776 **B. FDA Review of IDE Applications**

777 Sponsors should submit their signed IDE application together with accompanying materials
778 to CDRH's or CBER's Document Control Center (DCC) in accordance with the guidance
779 entitled "eCopy Program for Medical Device Submissions"
780 ([http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocu](http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm313794.pdf)
781 [ments/ucm313794.pdf](http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm313794.pdf)). Upon receipt of an IDE application, sponsors are notified in writing
782 of the date that FDA received the original application and the IDE number assigned. The 30
783 day review clock for the IDE application begins on the date stated in the acknowledgement
784 letter to the sponsor.

785 Each IDE application received in CDRH's DCC or CBER's DCC is routed to the appropriate
786 Division, and assigned to a reviewer or review team. The IDE application is first screened for
787 required content. If the IDE application contains adequate information for review, the review
788 team then reviews the IDE application within 30 days of receipt. FDA will inform the
789 sponsor of its decision, or notify the sponsor that the investigation may not begin, within 30
790 days from the date of receipt of the IDE application.³⁹

791
792 If an IDE application is approved or approved with conditions, the sponsor may begin subject
793 enrollment, up to the number of subjects and investigational sites specified in FDA's decision
794 letter, once allowed to proceed under IND, if applicable, and upon receipt of IRB approval,
795 which may occur prior to FDA approval. If FDA does not have outstanding issues that the
796 sponsor needs to address to support the study of the subject cohort under the proposed
797 investigational plan, the IDE will be approved without conditions. Alternatively, if FDA has
798 identified issues that need to be addressed in a timely manner but do not preclude initiation of
799 subject enrollment in the clinical investigation, the IDE will be approved *with* conditions. In
800 the case of approval with conditions, approval is granted and study enrollment may begin
801 immediately on the condition that, within 45 days from the date of FDA's decision letter, the
802 sponsor submits information addressing the issues identified in FDA's letter.

803
804 In certain instances, resolution of outstanding issues may be necessary before initiation of
805 subject enrollment. In these instances, the IDE will be disapproved in accordance with 21
806 CFR 812.30, meaning that the sponsor may not initiate subject enrollment in the
807 investigation until the sponsor addresses the issues identified in FDA's letter and receives an
808 approval or approval with conditions letter. In cases of disapproval of the IDE, a sponsor has
809 the opportunity to respond to the deficiencies by submitting an amendment or, in accordance
810 with 21 CFR 812.30(c)(1), to request a regulatory hearing under 21 CFR Part 16.

811
812 The guidance entitled "FDA Decisions for Investigational Device Exemption Clinical
813 Investigations"
814 ([http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceD](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM279107.pdf)
815 [ocuments/UCM279107.pdf](http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM279107.pdf)) provides additional information on this topic.

³⁹ If FDA does not, within 30 days, notify the sponsor that the study may not begin, the IDE application will be deemed approved, unless the device is a banned device, in accordance with 21 CFR 812.30(a).